Intrigued by recent findings linking the high activity of the mevalonate pathway to enhanced transcription by mutant p53 in MDA-MB-231 [42] but potentially in breast cancer stem cells as well [43], we tested but found no significant changes in p53 mRNA or protein levels (Sup Fig. S3). This evidence concerns the gene TP53 and breast carcinoma.